Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.57 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9164398 | 0.85 | LMNA (0.59) | KMT2ALMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL5188523 | 0.82 | SMN1; SMN2 (0.68) | KMT2AL3MBTL1LMNASMN1; SMN2NPC1 | |
| SCHEMBL26741098 | 0.82 | SMN1; SMN2 (0.58) | KMT2ALMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL26741094 | 0.82 | SMN1; SMN2 (0.58) | KMT2ALMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL14643391 | 0.81 | KDM4E (0.63) | KMT2AKDM4EL3MBTL1LMNANPC1 | |
| SCHEMBL5152296 | 0.81 | KMT2A (0.63) | KMT2AKDM4EL3MBTL1SMN1; SMN2RAB9A | |
| SCHEMBL10027975 | 0.81 | KDM4E (0.63) | KMT2AKDM4EL3MBTL1LMNANPC1 | |
| SCHEMBL12125170 | 0.81 | KDM4E (0.63) | KMT2AKDM4EL3MBTL1LMNANPC1 | |
| SCHEMBL19935743 | 0.81 | KMT2A (0.49) | KMT2AKDM4EL3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL19576325 | 0.81 | KMT2A (0.49) | KMT2AKDM4EL3MBTL1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940724-B2 | Quinoline derivitives and their uses | AMGEN INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8765940-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | KMT2A 679/4885KDM4E 1436/4885L3MBTL1 2670/4885 |
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | KMT2A 880/4885KDM4E 2124/4885L3MBTL1 2963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.